Month: February 2020

PunaMusta Media -konsernin tilinpäätös 1.1.-31.12.2019

Written by Customer Service on February 28, 2020. Posted in Earnings Releases And Operating Results.

PUNAMUSTA MEDIA OYJ TILINPÄÄTÖSTIEDOTE 28.2.2020 KLO 13.30 1(16)PUNAMUSTA MEDIA -KONSERNIN TILINPÄÄTÖS 1.1.–31.12.2019LOKA-JOULUKUU 2019 LYHYESTI– Konsernin liikevaihto kasvoi 3,6 % ja oli 29,8 miljoonaa euroa (28,8 miljoonaa euroa).– Liiketulos oli -0,1 (0,0) miljoonaa euroa ja tulos ennen veroja 0,0 (1,4) miljoonaa euroa. – Liiketoiminnan nettorahavirta oli 6,5 (-0,7) miljoonaa euroa.– Laimentamaton osakekohtainen tulos oli 0,06 (0,10) euroa.TAMMI-JOULUKUU 2019 LYHYESTI– Konsernin liikevaihto kasvoi 22,6 % ja oli 107,4 miljoonaa euroa (87,6 miljoonaa euroa).– Liiketulos oli 0,7 (0,7) miljoonaa euroa ja tulos ennen veroja 2,0 (2,4) miljoonaa euroa. – Liiketoiminnan nettorahavirta oli 11,8 (1,4) miljoonaa euroa.– Omavaraisuusaste oli 45,3 % (52,3 %).– Sijoitetun pääoman...

Form 8.3 – NMC Health Plc

Written by Customer Service on February 28, 2020. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

AFARAK GROUP PLC: FINANCIAL STATEMENTS RELEASE 2019

Written by Customer Service on February 28, 2020. Posted in Earnings Releases And Operating Results.

11:30 London, 13:30 Helsinki, 28 February 2020 – Afarak Group Plc (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR)AFARAK GROUP PLC: FINANCIAL STATEMENTS RELEASE 2019QUARTER FOUR 2019 HIGHLIGHTSRevenue for the fourth quarter of 2019 decreased by 39.2% to EUR 28.6 (Q4/2018: 47.0) million on account of lower sales volumes and lower selling prices;Processed material sold decreased by 34.5%, to 16,914 (Q4/2018: 25,833) tonnes;Tonnage mined decreased by 28.8%, to 73,021 (Q4/2018: 102,562) tonnes due to the temporarily discontinued mining activity at the South African mines;The Group’s EBITDA decreased to EUR -6.3 (Q4/2018: 1.0) million and the EBITDA margin at -22.1% (Q4/2018: 2.1%);EBIT was EUR -15.4 (Q4/2018: -7.0) million and the EBIT margin at -53.8% (Q4/2018: -14.9%);An impairment write-down...

AFARAK GROUP OYJ: TILINPÄÄTÖSTIEDOTE 2019

Written by Customer Service on February 28, 2020. Posted in Earnings Releases And Operating Results.

12:30 Lontoo, 13:30 Helsinki, 28.2.2020 – Afarak Group Oyj (”Afarak” tai ”Yhtiö) (LSE: AFRK, NASDAQ: AFAGR)AFARAK GROUP OYJ:N TILINPÄÄTÖSTIEDOTE 2019VUODEN 2019 NELJÄNNEN NELJÄNNEKSEN YHTEENVETOLiikevaihto laski 39,2 prosenttia 28,6 miljoonaan euroon (Q4/2018 47,0) alhaisempien myyntivolyymien ja alhaisempien myyntihintojen takia;Jalostettujen tuotteiden myynti laski 34,5 prosenttia 16 914 tonniin (Q4/2018 25 833 tonnia);Louhittu tonnimäärä laski 28,8 prosenttia 73 021 tonniin (Q4/2018: 102 562) Etelä-Afrikan kaivoksilla väliaikaisesti keskeytetyn kaivostoiminnan takia;Konsernin käyttökate laski -6,3 miljoonaan euroon (Q4/2018: 1,0) ja käyttökateprosentti oli -22,1 (Q4/2018: 2,1);Liikevoitto oli -15,4 miljoonaa euroa (Q4/2018: -7,0) ja liikevoittoprosentti -53,8 (Q4/2018: -14,9);Mogalen liiketoimintoihin liittyvistä muista pitkäaikaisista...

Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

Written by Customer Service on February 28, 2020. Posted in Public Companies.

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s CancerXMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020Company to present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the American Association for Cancer Research (AACR) Annual MeetingCAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended...

Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results

Written by Customer Service on February 28, 2020. Posted in Public Companies.

PALATINE, Ill., Feb. 28, 2020 (GLOBE NEWSWIRE) — Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2019.The Company reported an operating income of $0.3 million for the third quarter 2019 compared to an operating loss of $1.0 million for the same period in 2018. For the nine months ended September 30, 2019, the Company reported an operating loss of $1.0 million compared to an operating loss of $3.7 million for the same period in 2018.The Company reported net income of $0.2 million or $0.00 per diluted share for the third quarter 2019 compared to a net...

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Written by Customer Service on February 28, 2020. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2020 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for infusion (tradename to be determined in EU), has passed validation and is now under evaluation by the European Medicines Agency (EMA). The MAA for Pediatric Use Marketing Authorization (PUMA) was filed in early February 2020 for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. “The EMA validation of our marketing application represents another step forward in our efforts to address, if authorized, the critical unmet medical...

Regarding recommendation of the working group set up by the Ministry of Finance and the proposal to approve the actions authorizing to prepare for the initial public offering of shares of UAB Ignitis Grupė

Written by Customer Service on February 28, 2020. Posted in Public Companies.

UAB Ignitis Grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.The Company informs that on 28th February 2020 it received a letter (hereinafter referred to as the “Letter”) from the Ministry of Finance of the Republic of Lithuania, the authority implementing the rights of the sole shareholder of the Company (hereinafter referred to as the “Ministry of Finance”), notifying that on 28th February 2020 the working Group, which assessed the alternatives of long-term financing of the Company (hereinafter the “Working Group”), submitted its recommendation (hereinafter the “Recommendation”).It is stated in the Recommendation that, having considered all alternatives...

Dėl Finansų ministerijos inicijuotos darbo grupės rekomendacijų ir siūlymo pritarti UAB „Ignitis grupė“ pirminio viešo akcijų siūlymo inicijavimo veiksmams

Written by Customer Service on February 28, 2020. Posted in Public Companies.

UAB „Ignitis grupė“ (toliau – Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.Bendrovė informuoja, kad 2020 m. vasario 28 d. gavo jos vienintelio akcininko teises įgyvendinančios Lietuvos Respublikos finansų ministerijos (toliau – Finansų ministerija) raštą (toliau – Raštas), kuriuo informuojama apie tai, kad Bendrovės ilgalaikio finansavimo alternatyvas vertinusi darbo grupė (toliau – Darbo grupė) 2020 m. vasario 28 d. pateikė savo rekomendacijas (toliau – Rekomendacijos).Rekomendacijose nurodoma, kad, įvertinusi visas svarstytas Bendrovės ilgalaikio finansavimo alternatyvas, Darbo grupė priėjo prie išvados, jog iš galimų akcinio kapitalo pritraukimo būdų efektyviausias...

Grace Increases Share Repurchase Authorization to $250 Million

Written by Customer Service on February 28, 2020. Posted in Public Companies.

COLUMBIA, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) — W. R. Grace & Co. (NYSE:GRA) today announced that its Board of Directors increased its share repurchase authorization to $250 million, including approximately $83 million remaining under its previously-announced program. In the first quarter, Grace has repurchased more than $25 million of its common stock. Since February 2014, the company has repurchased approximately $1.2 billion of its common stock.“We are confident in our long-term growth drivers and the payback on the commercial excellence and operating excellence investments we are making,” said Hudson La Force, Grace’s President and Chief Executive Officer. “This authorization demonstrates our continued commitment to increasing long-term shareholder value. Our strong balance sheet and cash flow provide the flexibility to...

Month: February 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals